Humacyte (NASDAQ:HUMA – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.
Institutional and Insider Ownership
44.7% of Humacyte shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 11.2% of Humacyte shares are owned by insiders. Comparatively, 6.3% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk & Volatility
Humacyte has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Humacyte | $1.57 million | 408.84 | -$110.78 million | ($1.34) | -3.81 |
| Protalix BioTherapeutics | $45.67 million | 3.42 | $8.31 million | ($0.13) | -16.31 |
Protalix BioTherapeutics has higher revenue and earnings than Humacyte. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Humacyte and Protalix BioTherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Humacyte | N/A | -942.81% | -93.82% |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Humacyte and Protalix BioTherapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Humacyte | 0 | 1 | 6 | 1 | 3.00 |
| Protalix BioTherapeutics | 0 | 0 | 0 | 0 | 0.00 |
Humacyte presently has a consensus target price of $13.71, suggesting a potential upside of 168.91%. Given Humacyte’s stronger consensus rating and higher possible upside, research analysts clearly believe Humacyte is more favorable than Protalix BioTherapeutics.
Summary
Humacyte beats Protalix BioTherapeutics on 10 of the 15 factors compared between the two stocks.
About Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
